ESR1 and breast cancer: For patients with ER+ breast cancer exhibiting high levels of TRIM33 and ER, TRIM33 inhibition may be considered a therapeutic opportunity to downregulate ER and prevent estrogen-independent tumor growth, as is observed upon resistance to aromatase inhibitor therapy.